Literature DB >> 30571982

Efficacy of dapsone administered alone or in combination with diazepam to inhibit status epilepticus in rats.

Camilo Ríos1, Ana Cristina Farfán-Briseño2, Joaquín Manjarrez-Marmolejo3, Javier Franco-Pérez3, Marisela Méndez-Armenta4, Concepción Nava-Ruiz4, Sara Caballero-Chacón5, Amairani Ruiz-Diaz4, Verónica Baron-Flores6, Araceli Díaz-Ruiz7.   

Abstract

Status epilepticus (SE) is a serious medical condition, as it may trigger epileptogenesis. SE produces continuous generalized seizures resulting in irreversible brain damage. Therefore, the use of neuroprotective agents to prevent cell damage, may reduce the impact of SE. The use of diazepam (DZP), has shown limited neuroprotective effect in SE patients. According to previous reports, dapsone (DDS) is able to reduce both cell damage and seizures, when administered 30 min before the onset of seizures. This study is aimed to evaluate the ability of DDS, alone or in combination with DZP starting their administration once the SE is onset to evaluate the control of seizures in rats. Results showed a reduced convulsive electrical activity after 30 min, 1 and 2 h after SE induced by kainic acid (KA) administration, in the animals treated with DZP alone or in combination with DDS. At 24 h, we observed electrical activity similar to baseline in all groups receiving treatment. The animals treated with DDS and DZP alone or in combination showed an increase in the number of viable pyramidal cells but only the combination showed a lower number of damaged pyramidal neurons of hippocampal CA3. In conclusion, DDS plus DZP was able to control SE and to prevent SE-induced damage, when administered in combination with DZP. As DDS is already in use for patients with leprosy, that combination may be a safe, good option for human cases of SE.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dapsone; Diazepam; Kainic acid; Rats; Status epilepticus

Mesh:

Substances:

Year:  2018        PMID: 30571982     DOI: 10.1016/j.brainres.2018.12.017

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats.

Authors:  Mohammad Sheibani; Sadaf Nezamoleslami; Hedyeh Faghir-Ghanesefat; Amir Hossein Emami; Ahmad Reza Dehpour
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-08       Impact factor: 3.333

2.  Dapsone improves the vincristine-induced neuropathic nociception by modulating neuroinflammation and oxidative stress.

Authors:  Sevda Shayesteh; Mina Khalilzadeh; Nasrin Takzaree; Ahmad Reza Dehpour
Journal:  Daru       Date:  2022-09-15       Impact factor: 4.088

Review 3.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

4.  Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.

Authors:  Richard E Kast
Journal:  Med Sci (Basel)       Date:  2021-02-16

Review 5.  Dapsone, More than an Effective Neuro and Cytoprotective Drug.

Authors:  Araceli Diaz-Ruiz; Juan Nader-Kawachi; Francisco Calderón-Estrella; Alfonso Mata-Bermudez; Laura Alvarez-Mejia; Camilo Ríos
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.